Patents Examined by R. Clarke
  • Patent number: 11952559
    Abstract: This present disclosure relates to novel detergent compositions comprising bacterial mannanase enzymes. The detergent compositions comprising bacterial mannanases are useful in laundry and cleaning applications wherein degradation or modification of mannan is desired. The present disclosure also relates to the use of said detergent compositions in laundry and cleaning applications as well as a method for degrading mannan.
    Type: Grant
    Filed: March 1, 2018
    Date of Patent: April 9, 2024
    Assignee: AB Enzymes Oy
    Inventors: Daniela Herbst, Susanne Wieland, Nina Mussmann, Taija Leinonen, Leena Valtakari, Michael Seefried, Kari Juntunen, Daniela Dollak, Patrick Lorenz, Jari Vehmaanperae, Pentti Ojapalo, Terhi Puranen, Kristiina Jaervinen
  • Patent number: 11946853
    Abstract: A apparatus for detecting cells or particles in a fluid container includes a dispenser configured to dispense at least one cell or at least one particle into a defined sub-volume of a fluid with which the fluid container is at least partially filled, and a detection apparatus configured to, in a time-coordinated manner with dispensing the at least one cell or the at least one particle by the dispenser, perform a detection in the defined sub-volume and/or in one or several sub-volumes underneath the defined sub-volume in order to sense the at least one cell or the at least one particle when entering the fluid or immediately after entering the fluid.
    Type: Grant
    Filed: August 6, 2021
    Date of Patent: April 2, 2024
    Assignee: cytena GmbH
    Inventors: Jonas Schoendube, Andre Gross
  • Patent number: 11944651
    Abstract: The present invention aims to provide an antimicrobial and antiviral agent which comprises a naturally occurring component as an active ingredient and is effective against microbes including various classes of fungi and viruses. In one aspect of the present invention, provided is an antimicrobial and antiviral agent comprising Lactobacillus derived from Artemisia indica var. maximowiczii.
    Type: Grant
    Filed: September 8, 2021
    Date of Patent: April 2, 2024
    Assignee: Murata Manufacturing Co., Ltd.
    Inventors: Masachika Takata, Hirofumi Sunahara
  • Patent number: 11859226
    Abstract: The present invention relates to a newly isolated bacterium belonging to the genus Microbacterium, a composition for producing psicose comprising the strain, and a method for producing psicose using the same.
    Type: Grant
    Filed: December 26, 2017
    Date of Patent: January 2, 2024
    Assignee: SAMYANG CORPORATION
    Inventors: Bu-Soo Park, Eun Jin Han, Sang-Hee Lee, Soun Gyu Kwon, Jin Ha Kim, Chong Jin Park
  • Patent number: 11834650
    Abstract: The present invention relates to methods of transforming a cell by use of an acoustic transducer. In particular embodiments, the radiofrequency signal to the transducer can be tuned to provide optimal membrane disruption of the cell; and an agent, such as a nucleic acid, can then be delivered to the cell.
    Type: Grant
    Filed: June 20, 2019
    Date of Patent: December 5, 2023
    Assignee: National Technology & Engineering Solutions of Sandia, LLC
    Inventors: Anne Ruffing, Darren W. Branch, Ronald P. Manginell
  • Patent number: 11821895
    Abstract: The disclosure provides methods of making functional cortical organoids from somatic cells and stem cells and methods of using the functional organoids.
    Type: Grant
    Filed: July 26, 2018
    Date of Patent: November 21, 2023
    Assignee: The Regents of the University of California
    Inventors: Alysson Renato Muotri, Priscilla Davidson Negraes, Cleber Trujillo, Pinar Mesci
  • Patent number: 11802271
    Abstract: The present invention relates to a method for irradiating a population of mammalian cells comprising at least one target mammalian cell with electron beams and/or X-rays, characterized in that: (i) a composition comprising a population of mammalian cells is irradiated in vitro with electron beams and/or X-rays, the population of mammalian cells containing at least one target mammalian cell and the dose rate being within the range from 5 Gy/sec to 107 Gy/sec, and (ii) optionally viable target mammalian cells are isolated or enriched from the population of mammalian cells, and to agents obtainable thereby and to uses thereof.
    Type: Grant
    Filed: March 14, 2018
    Date of Patent: October 31, 2023
    Assignee: FRAUNHOFER-GESELLSCHAFT ZUR FÖRDERUNG DER ANGEWANDTEN FORSCHUNG E.V.
    Inventors: Frank-Holm Rögner, Sebastian Ulbert, Jana Burkhardt, Javier Portillo, Jessy Schönfelder
  • Patent number: 11802270
    Abstract: The present invention provides, among other things, methods for producing platelets including the steps of providing a silk membrane about 2 ?m and 100 ?m thick, inclusive, contacting the silk membrane with a porogen to form a porous silk membrane comprising at least one silk wall defining a lumen, associating the porous silk membrane with stromal derived factor-1? and at least one functionalizing agent, forming a three dimensional silk matrix comprising interconnected pores wherein the pores have a diameter of between about 5 and 500 ?m, inclusive, wherein the silk matrix is formed around at least a portion of the porous silk membrane, introducing a plurality of megakaryocytes to the silk matrix such that the megakaryocytes are located at least partially within the porous silk matrix, and stimulating the plurality of megakaryocytes to produce platelets. Also provided are various new compositions and methods of making those compositions.
    Type: Grant
    Filed: August 6, 2015
    Date of Patent: October 31, 2023
    Assignees: Tufts University, University of Pavia
    Inventors: Alessandra Balduini, David L. Kaplan, Lindsay Wray, Christian Andrea Di Buduo, Lorenzo Tozzi
  • Patent number: 11781167
    Abstract: Provided is a method of continuous glucose monitoring (CGM) comprising using an FAD-GDH. The FAD-GDH is capable of retaining initial activity over a certain period of time. Also provided is a method for screening for an FAD-GDH suitable for use in CGM as well as a CGM device comprising an FAD-GDH.
    Type: Grant
    Filed: March 30, 2018
    Date of Patent: October 10, 2023
    Assignee: Kikkoman Corporation
    Inventor: Yosuke Masakari
  • Patent number: 11767542
    Abstract: Waste gas mixtures produced and used in industry may contain harmful sulphurous compounds. The present disclosure provides a method for treatment of gas mixtures contaminated with harmful sulphurous compounds by using microorganisms capable of degrading said harmful sulphurous compounds which involves controlling nitrate levels in the medium in which microbiological conversion of harmful sulphurous compounds takes place at high levels.
    Type: Grant
    Filed: December 20, 2019
    Date of Patent: September 26, 2023
    Inventor: Bonno Koers
  • Patent number: 11768135
    Abstract: An automated specimen preparation system for preparing a specimen from a sample in a sample container is provided. The automated specimen preparation system comprises a specimen transfer device configured for holding a specimen collector thereon and for being positioned within the sample container. The specimen transfer device comprises a central bore having an open distal end and a closed proximal end, a pressure monitoring port fluidly coupled to the central bore at the proximal end of the central bore, and a fluid waste evacuation port fluidly coupled to the proximal end of the central bore. The pressure monitoring port comprises a reduced diameter portion coupled directly to the central bore. The automated specimen preparation system further comprises a vacuum source fluidly coupled to the fluid waste evacuation port, and a pressure monitoring device fluidly coupled to the pressure monitoring port.
    Type: Grant
    Filed: August 29, 2018
    Date of Patent: September 26, 2023
    Assignee: Hologic, Inc.
    Inventors: Raymond Jenoski, Eric Grimes
  • Patent number: 11753614
    Abstract: The present invention relates to a novel violaxanthin-overproducing strain of Chlorella vulgaris and a method of producing violaxanthin therefrom. The inventors have developed a strain that produces violaxanthin at a significantly higher level than a wild-type strain by inducing a random chemical mutation in a Chlorella vulgaris strain to, and then as a result of analysis, confirmed that the strain produces violaxanthin up to 0.41% based on dry weight, which reaches the highest level that is possible to be produced in microalgae. Furthermore, as a method of effectively extracting a carotenoid pigment containing violaxanthin from the strain was established, since the strain and the developed pigment extraction method according to the present invention allow effective production and separation of violaxanthin, the strain is expected to increase commercial applications such as cosmetics, health functional foods and feed.
    Type: Grant
    Filed: February 2, 2021
    Date of Patent: September 12, 2023
    Assignee: IUCF-HYU (INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY)
    Inventors: Eon Seon Jin, Jongrae Kim
  • Patent number: 11701401
    Abstract: The present invention relates to an herbal composition in powder, pill or liquid form for speeding up fracture healing and bone regeneration, which may promote fracture healing and bone regeneration by containing medicinal herbs capable of improving fracture healing and bone regeneration and medicinal herbs capable of enhancing digestion and absorption, and an herbal formulation in powder, pill or liquid form containing the same. The herbal composition in powder, pill or liquid form for speeding up fracture healing and bone regeneration according to the present invention contains 20 parts by weight of Angelica gigas, 16 parts by weight of Dendrobium moniliforme, 12 parts by weight of Dipsaci radix, 10 parts by weight of antler, 8 parts by weight of Cnidium officinale, 8 parts by weight of Astragalus membranaceus, 4 parts by weight of Achyranthes japonica, and 4 parts by weight of Massa medicata fermentata.
    Type: Grant
    Filed: March 11, 2022
    Date of Patent: July 18, 2023
    Inventor: Young Jin Choi
  • Patent number: 11692163
    Abstract: A system and method for the production of microbial consortiums and by-product material is provided. A physical containment system comprising phase spaces arranged in a discrete order to favor specific biological reactions is also provided. Phase profiles and phase data sets include the pre-determined physical and biological parameters for the phase space transitions. Movement of material from one phase to the next is hydraulically balanced enabling working fluid to continuously move in a fixed direction and rate of flow. Continuous monitoring of phase profiles and phase data sets provide feedback to the system enabling alteration of the conditions in the system to control reactions therein.
    Type: Grant
    Filed: May 12, 2022
    Date of Patent: July 4, 2023
    Assignee: Tenfold Technologies, LLC
    Inventors: Robert Chisholm, Michael LaMontagne, Robert N. Ames, David P. Lanciault, John R. Coyne
  • Patent number: 11649432
    Abstract: The present invention provides a method for more efficiently producing retinal pigment epithelial cells from pluripotent stem cells. The method of the present invention for producing retinal pigment epithelial cells includes the following steps: (1) a first step for culturing a pluripotent stem cell in a medium comprising an FGF receptor inhibitor and/or an MEK inhibitor for a period of not more than 30 days, and (2) a second step for culturing the cell obtained in the first step in the presence of a Nodal signal transduction pathway inhibitor and/or a Wnt signal transduction pathway inhibitor to form a retinal pigment epithelial cell.
    Type: Grant
    Filed: September 8, 2016
    Date of Patent: May 16, 2023
    Assignees: SUMITOMO PHARMA CO., LTD., HEALIOS K.K.
    Inventors: Satoshi Ando, Takao Kuroda
  • Patent number: 11649430
    Abstract: A method of promoting fungal spore germination. The method includes the step of contacting a fungal spore with a germination-promoting concentration of an exogenous imizoquin.
    Type: Grant
    Filed: August 26, 2019
    Date of Patent: May 16, 2023
    Assignee: Wisconsin Alumni Research Foundation
    Inventor: Nancy P. Keller
  • Patent number: 11633438
    Abstract: The present invention comprises the discovery and development of an effective cryoprotectant composition, without containing skim milk or any other animal-derived compounds, to achieve long-term stability of freeze-dried lactic acid bacteria (LAB), at different temperatures, whereby the retention of viability of the freeze-dried LAB after 6 months of storage, preferably after 9 months of storage, more preferably after 12 months of storage is more than 50%. The invention is in the field of producing freeze dried bacteria, in particular Lactic acid bacteria. More in particular, the invention relates to the use of a novel combination of cryoprotectants for increasing the viability of bacteria after freeze drying, improving the texture of the lyofilized cake for easy grinding and improving the long term stability of the freeze dried bacteria at different temperature conditions. The invention further relates to such freeze dried bacteria for use in food industry or in human or animal health applications.
    Type: Grant
    Filed: February 5, 2020
    Date of Patent: April 25, 2023
    Assignee: INTREXON ACTOBIOTICS NV
    Inventors: Sam Corveleyn, Patrick Dhaese, Sabine Neirynck, Lothar Steidler
  • Patent number: 11628190
    Abstract: A method of treating neurodegenerative diseases using hUCB plasma is presented herein. hUCB plasma attenuated the hyperactive response (Group III) and potentiated the normal response in Group I ALS patients, but did not alter that of the non-responders to PHA (Group II). The elevated activity of caspase 3/7 observed in the MNCs from ALS patients was significantly reduced by hUCB plasma treatment. The ability of hUCB plasma to modulate the mitogen cell response and reduce caspase activity suggest that the use of hUCB plasma alone, or with stem cells, may prove useful as a therapeutic in ALS patients. hUCB plasma was shown to increase therapeutic efficacy of MNCs as well as decrease apoptosis of MNCs. The cytokine profile of hUCB plasma supports its usefulness as a sole therapeutic as well as an additive to MNCs.
    Type: Grant
    Filed: October 17, 2019
    Date of Patent: April 18, 2023
    Assignees: University of South Florida, Saneron CCEL Therapeutics, Inc.
    Inventors: Svitlana Garbuzova-Davis, Jared Carl Ehrhart, Paul R. Sanberg
  • Patent number: 11623213
    Abstract: A microbiological testing device for testing a liquid to be analysed that is liable to contain at least one microorganism, includes a closed inner space, a microbiological filtration member and an inlet port. The device has a nutritive layer in contact with the filtration member, and in that, in a configuration for providing the device an open/close member of the inlet port is in a closed state; the absolute gas pressure inside the closed inner space is strictly less than the standard atmospheric pressure, such that the device is able to create suction through the inlet port during a first opening of the open/close member.
    Type: Grant
    Filed: April 10, 2018
    Date of Patent: April 11, 2023
    Assignee: BIOMÉRIEUX SA
    Inventors: Florian Michel, Frédéric Foucault, Christine Rozand
  • Patent number: 11597910
    Abstract: Medical instrument includes a substrate, in which cells are in contact with or held on a surface of the substrate, and at least the surface of the substrate which holds the cells is formed of a fluorine-containing cyclic olefin polymer which contains a repeating structure unit represented by Formula (1), wherein in Formula (1), at least one of R1 to R4 is fluorine, an alkyl with 1 to 10 carbon atoms which contains fluorine, an alkoxy with 1 to 10 carbon atoms which contains fluorine, or an alkoxyalkyl with 2 to 10 carbon atoms which contains fluorine, R1 to R4 are selected from hydrogen and certain non-fluorinated groups when R1 to R4 do not contain fluorine, R1 to R4 may be the same as or different from each other, and R1 to R4 may be bonded to each other to form a cyclic structure.
    Type: Grant
    Filed: August 10, 2015
    Date of Patent: March 7, 2023
    Assignee: MITSUI CHEMICALS, INC.
    Inventors: Tadahiro Sunaga, Takashi Oda, Hiroshi Miyasako, Takeshi Osaka